Evidence map›Paper›PMID 40436757›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Methotrexate-Associated Lymphoproliferative Disorder Presenting as Obstructive Jaundice Due to Pancreatic Involvement.

Yasuhiro Okuda, Shinya Nakamura, Yasutaka Ishii, Yumiko Tatsukawa, Juri Ikemoto, Sayaka Miyamoto, Masaru Furukawa, Kazuki Nakamura, Noriaki Iijima, Risa Nomura and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasuhiro OkudaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Shinya NakamuraDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Yasutaka IshiiDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Yumiko TatsukawaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Juri IkemotoDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Sayaka MiyamotoDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Masaru FurukawaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Kazuki NakamuraDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Noriaki IijimaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Risa NomuraDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
Tetsumi YoshidaDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 73-year-old man with a 13-year history of methotrexate (MTX) therapy for rheumatoid arthritis presented with jaundice and hepatic dysfunction. Contrast-enhanced computed tomography revealed hypovascular masses in the pancreas, small intestine, and thyroid lobes. A biopsy confirmed diffuse large B-cell lymphoma (DLBCL), leading to the diagnosis of MTX-associated lymphoproliferative disorder (MTX-LPD), a rare condition with pancreatic involvement. MTX was discontinued and R-CHOP therapy was initiated. Although a spontaneous regression of MTX-LPD can occur, early intervention may be warranted in select cases, thus highlighting the need for an individualized management approach.

Indexed as

Antirheumatic AgentsJaundice, ObstructiveLymphoma, Large B-Cell, DiffuseLymphoproliferative DisordersMethotrexateAgedAntineoplastic Combined Chemotherapy ProtocolsArthritis, RheumatoidCyclophosphamideDoxorubicinHumansMalePrednisoneRituximabVincristineAntirheumatic AgentsCyclophosphamideDoxorubicinMethotrexatePrednisoneR-CHOP protocolRituximabVincristinelymphomalymphoproliferative disordersmethotrexatepancreas

Identifiers

PMID40436757
PMCPMC12740389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.